

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicants:

THASTRUP et al.

Conf.:

1691

Appl. No.:

09/619,310

Group:

1642

Filed:

July 19, 2000

Examiner:

S. L. Rawlings

For:

NOVEL FLUORESCENT PROTEINS

LARGE ENTITY TRANSMITTAL FORM

Assistant Commissioner for Patents Washington, DC 20231

October 18, 2002

BOX SEQUENCE

PATENT 3759-0106P

Sir:

Transmitted herewith is an amendment in the above-identified application.

The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.

The enclosed document is being transmitted via facsimile.


The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	37	-	37	=	0	\$ 18	\$0.00
INDEPENDENT	3	-	3	=	0	\$ 84	\$0.00
FIRST PRESENTATION OF A MULTIPLE CLAIM						\$280	\$0.00
						TOTAL	\$0.00

Application No. 09/619,310) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and Petition for 1.136(a). \$0.00 for the extension of time. \boxtimes No fee is required. A check in the amount of \$0.00 is enclosed. Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate. If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees. Respectfully submitted, BIRCH, STEWART, KOLASCHI & BIRCH, LLP Leonard R. Svensson, Reg. No. 30,330 P.O. Box 747 Falls Church, VA 22040-0747 LRS/KR/LPS (703) 205-8000 3759-0106P

(Rev. 01/22/01)





BOX SEQUENCE PATENT

3759-0106P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicants:

THASTRUP et al.

Conf.: 1691

Appl. No.:

09/619,310

Group: 1642

Filed:

July 19, 2000

Examiner:

S. L. Rawlings

October 18, 2

For:

NOVEL FLUORESCENT PROTEINS

AMENDMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed September 18, 2002, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

IN THE SPECIFICATION:

Please replace the following paragraphs inserted on August 22, 2002 at page 7, line 9, regarding Fig. 1 to Fig. 5, only, with the following paragraphs:

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a map of the pUC19-GFP plasmid construction;

Fig. 2a is the DNA (SEQ ID NO:21) and predicted primary amino acid sequence

(SEO ID-NO:22) of GFP: